GlassScriptPhysician profile
Zulfiqar Arif
NPI 1790030724
$4,155.05
in general payments reported to CMS, 2019-2025
29 companies · $1,990 in 2025
The $1,990 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $695 · 2020: $49.74 · 2021: $13.89 · 2022: $15.97 · 2024: $1,391 · 2025: $1,990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $625.14 | 2019-2025 | |
| Novo Nordisk INC | $571.18 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $411.19 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Lilly USA, LLC | $326.25 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Astellas Pharma US INC | $295.84 | 2024-2025 | Veozah |
| Abbvie INC. | $241.09 | 2024-2025 | |
| Intra-Sana Laboratories | $229.56 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Bayer Healthcare Pharmaceuticals INC. | $176.89 | 2024-2025 | |
| Amgen INC. | $162.92 | 2019-2025 | Evenity, Repatha, Otezla |
| Abbott Laboratories | $159.44 | 2024-2025 | Freestyle Libre 3 |
| Eisai INC. | $123.48 | 2024 | |
| Glaxosmithkline, LLC. | $116.78 | 2024-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Almatica Pharma LLC | $105.08 | 2024-2025 | Loreev Xr, Teriparatide |
| Phathom Pharmaceuticals, INC. | $84.70 | 2024 | Voquezna |
| Exact Sciences Corporation | $75.28 | 2024-2025 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $58.33 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.21 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $50.74 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $49.75 | 2024-2025 | Rexulti |
| Genentech USA, INC. | $42.85 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $32.98 | 2022-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.09 | 2019 | |
| Lundbeck LLC | $26.59 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $26.05 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Biogen, INC. | $20.52 | 2025 | Skyclarys |
| Regeneron Healthcare Solutions, INC. | $16.12 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.19 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.07 | 2019 | |
| Currax Pharmaceuticals LLC | $13.74 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zulfiqar Arif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.